英文互译镜像站

Pramipexole/ondansetron

Last updated
Pramipexole/ondansetron
Combination of
Pramipexole Dopamine D2-like receptor agonist
Ondansetron Serotonin 5-HT3 receptor antagonist
Clinical data
Other namesOndansetron/pramipexole; ALTO-207; ALTO207; CTC-501; CTC501

Pramipexole/ondansetron, also known by its developmental code name ALTO-207 and formerly as CTC-501, is a combination of pramipexole, a dopamine D2-like receptor agonist, and ondansetron, a serotonin 5-HT3 receptor antagonist, which is under development for treatment-resistant major depressive disorder (TRD or MDD). [1] [2] The inclusion of ondansetron is to reduce the side effects of pramipexole like nausea and vomiting in order to allow for higher doses of pramipexole that may be more effective for treatment of depression as well as more rapid upward titration of pramipexole dosage. [2] The drug was originated by Chase Therapeutics and is being developed by Alto Neuroscience. [1] [2] As of March 2026, it is in phase 2 clinical trials for MDD. [1]

Contents

See also

References

  1. 1 2 3 "Ondansetron/Pramipexole". AdisInsight. 26 March 2026. Retrieved 6 April 2026.
  2. 1 2 3 "Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression". www.pharmabiz.com. 17 January 2026. Retrieved 6 April 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
网页镜像工具 镜像站群系统 开源整站镜像工具 站点核心词加权 关键词转码站群